INCC02_2017

Dear Valued Customer,

Adaltis S.r.l. proudly presents its new instrument family for fully automated microELISAprocessing. The instruments are newly designed, based on reliable and state of the art technology. Over 20-years experience in making automated microELISA instruments, we are
your trusted choice.

NEW - PERSONAL LAB

Fully automated 2-plate microELISA processor,
including IFA test options

NEW - NEXGEN

Fully automated 7-plate microELISA processor,
including IFA test options

Major Instrument characteristics:

• High throughput testing of microELISA, optional IFA testing can be done simultaneously
• ‘Kit-to-Instrument’ direct loading from reagents bottles/vials from kit, into the instrument
• Continuous liquid monitoring– for buffers and waste solution
• Latest technology for hardware, increased instrument precision and reliability
• Extremely reduced maintenance
• Easy user interface to program applications, protocols and run sessions
• Remote diagnostics/support of software and hardware

Advantages

• Less operator time needed for the instrument operation, long walk-away times
• Faster and more accurate, more optimised test routine of assays
• Most economic use of reagents, due to absence of pouring liquids into containers/vials
• One of the best serviceability of the instruments in the market of today

Reagent Tests
Our range of EIAgen microELISA assays are excellent combining with the new Personal LAB and new NEXgen instruments:

• Fully compatible CE-IVD assays for best and optimal performance
• Fully validated assays and proven combination ‘instrument & reagents from one source’
• Wide range of microELISA assays for blood banks (HIV, HBsAg,HCV, Syphilis, HTLV),
  serology, virology, ToRCH, thyroids, hormones, vitamins and many more.

Contact Adaltis for more information and sales opportunities via: sales@adaltis.net
or request a quote via:  request-a-quote form

Adaltis S.r.l. is launching its Molecular Diagnostic (MDx) products and solutions for PCR and Genomics

Regards,

Marco Spadaccioli
General Manager, Adaltis S.r.l.

Product: EIAgen 25 OH Vitamin D Total Kit - Ref: 1425OHVDT
Subject: Improved Product

We are pleased to inform you that as of today we are offering a new and improved Vitamin D kit that replaces the previous kit version
and that offers a number of advances and advantages.

In addition to being designated for optimal use with our automated systems NEXgen and Personal Lab (PLab), the kits can be used
with both serum and plasma samples, it offers reduced assay time to 1 hour, reduced specimen volume, and not the least it does not
require shaking in the incubation period.

Please review the enclosed information for the product specifications, advantages, and key differences from the previous version, or
download the product IFU at the link.

For any further information please contact our Customer Care Center at the Phone Number +39 051 437779, or via email at
info@adaltis.net. or for orders, please contact our Order Processing department via order@adaltis.net.

If you have any question please, contact our Sales Department via email at sales@adaltis.net.
We will be pleased to be at your service.

Product: EIAgen SARS-CoV-2 Kits

Subject: Release

We are pleased to inform you that The EIAgen line is completed with SARS-CoV-2 fast and reliable microplate assays, as a response to COVID-19 Emergency. Qualitative detection of IgM, IgG, IgA, antibodies to SARS-CoV-2 in human serum or plasma with the “Capture“ system. It is intended for evaluating the immune response of patients suspected to be infected by SARS-CoV-2, for sero-epidemiologic studies and as an aid in the diagnosis of Coronavirus disease 2019 (COVID-19).

Adaltis S.r.l. as a pioneer in ELISA assay development and microplate automation, presents three novel antibody assays for IgA, IgM and IgG ELISA microplate assays to detect the exposure to the SARS-CoV-2 virus. These in-vitro diagnostic assays are designed for manual to fully automated diagnosis of a Covid-19 infection in human beings.

The EIAgen SARS-CoV-2 assays are a perfect addition for SARS-CoV-2 detection done via molecular diagnostic techniques, and can serve as an essential methodology for epidemiological Covid-19 studies.

SARS-CoV-2 ELISA features & benefits:

- Separate detection of IgA, IgM, IgG

- Incubation below 2 hours

- Easy automation on a large range of automated microplate processors

- CE-IVD certified assay

Automation of EIAgen SARS-CoV-2 ELISA testing

With the iconic Personal LAB and NEXgen fully automated microplate processors you facilitate ease of automation with the EIAgen SARS-CoV-2 ELISA’s.

The three different antibody assays can be processed single or combined according to your needs in a range of varieties like IgM + IgG, IgA single, IgA + IgM + IgG, etc.

The EIAgen SARS-CoV-2 ELISA’s are validated applications on Personal LAB (2 microplate) and NEXgen (7 microplate), and provide you an instant start and trouble-free Covid-19 diagnostic testing routine. The EIAgen SARS-CoV-2 ELISA’s run seamlessly on Personal LAB and NEXgen, and provide you cost efficient and reliable test results.

Please products information click here.

For any further information please contact via email at covid19@adaltis.net

If you have any question please, contact our Sales Department via email at sales@adaltis.net.
We will be pleased to be at your service.

Product: MOLgen SARS-CoV-2 kit 

Subject: Informative Update

MOLgen SARS-CoV-2 kit by Adaltis, addressed to OMICRON (B.1.1.529) new variant:

MOLgen kits are available in two formats: 3 genes or 4 genes kits.

For the 4 genes kit the primer and probe set is designed to detect SARS-CoV-2 identifying 4 targets: 3 specific for SARS-CoV-2 (N gene, S Gene, E gene) and 1 common for sabercoviridae (RdRp gene).

The 3 genes kits containing only the N, E and RdRp and was proven as specific and sensitive, Favaro et al. Scientific Reports, 2021, 11, 18995.

The detection of amplified virus RNA fragment is performed in fluorimeter channel FAM (RdRp gene), ROX/Texas Red (E gene), Cy5.5/Alexa Fluor (S gene) and CY5 (N gene).

The use of human beta actina as Internal Control (IC) on HEX channel ensure the monitoring correct amplification and cellularity of the samples.

The results of PCR analysis are taken into account in complex diagnostics of disease. The kitis validated for use with various RT-PCR machines: AMPLilab (Adaltis) and CFX96 (Bio-Rad). The kits were proven valid asgians SARS-CoV-2 and it variation alpha, betta, gamma and delta.

As Omicron emerged as the new variant of concern (VOC) (Nature Nov 2021, https://www.nature.com/articles/d41586-021-03552-w?s=08), (WHO nov26 2021,https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern) we have studied its sequence compare to our primer sequence in our kits. Based on the currently known variation as published in https://www.gisaid.org/; https://nextstrain.org/;  https://cov-lineages.org/.

The new variant is highly mutated in the spike and RBD region. However, our MOLgen 4 genes kit is in such position where the S primers and probes chosen by Adaltis expert is evading the changes in the new variant. Hence this kit is still valid for OMICRON also in the S genes, which was under severe variation. The 3 gene kits, lacking S gene in also not affected by Omicron mutation, and it is still valid.

In conclusion, these mutations have no impact on the effectiveness or safety of the MOLgen assays.

Sincerely,
Adaltis Srl.

Learn about the product  MOLgen SARS CoV-2 RT-PCR KIT   Requests to: covid19@adaltis.net

IFU 4+1 Gene Kit   IFU 3 Gene Kit

                                                                                              Read & Download the Notice Document by click

30.04.2024

Avviso pubblico (IT)

MITUS - Micobatterio Tubercolosi and resistance System for fast identification

FESR Fondo Europeo di Sviluppo Regionale Programma Operativo regionale del Lazio Descrizione del Progetto: Adaltis in aggregazione con IASI-CNR partecipano al progetto MITUS che consentirà di acquisire nuove competenze e conoscenze nel campo della tecnologia RCA per la diagnosi della tubercolosi, che saranno utilizzate per sviluppare prodotti o servizi innovativi basati su tecnologie avanzate e altamente competitive Periodo di programmazione: 2021-2027 Contributo concesso: 530.486,37 Euro.

Public notice (EN)

MITUS - Mycobacterium Tuberculosis and resistance System for fast identification

ERDF European Regional Development Fund Lazio Regional Operational Program Description of the Project: Adaltis in aggregation with IASI-CNR participate in the MITUS project which will allow the acquisition of new skills and knowledge in the field of RCA technology for the diagnosis of tuberculosis, which will be used to develop innovative products or services based on advanced and highly competitive technologies Programming period: 2021-2027 Grant granted: 530,486.37 Euros.

                                                                                              Read & Download the Notice Document by click

21.11.2025

Public notice (EN)

Conclusion of the MYTUS Project: An Innovative System for the Rapid Identification of Mycobacterium tuberculosis and Drug Resistance, Ready for Real-World Applications
Rome–Guidonia, 21 November 2025

The MYTUS project has been completed. This research and innovation initiative was dedicated to the development of an advanced diagnostic system for the rapid identification of Mycobacterium tuberculosis (MTB) and the main genetic mutations associated with resistance to anti-tuberculosis drugs.

The project was funded under the Lazio ERDF Programme 2021–2027, Competitive Repositioning RSI, Life Sciences, approved by Determination No. G18823 of 28/12/2022, CUP F89J23001060007.

MYTUS was coordinated by ADALTIS SRL in collaboration with CNR IAS I.

Public notice (IT)

Conclusione progetto MYTUS: sistema innovativo per l’identificazione rapida di Mycobacterium tuberculosis e delle resistenze ai farmaci, pronto per applicazioni in contesti reali

Roma- Guidonia, 21 novembre 2025
Si è concluso MYTUS, progetto di ricerca e innovazione dedicato allo sviluppo di un sistema diagnostico avanzato per l’identificazione rapida del Mycobacterium tuberculosis (MTB) e delle principali mutazioni genetiche correlate alla resistenza ai farmaci antitubercolari.

Il progetto è stato finanziato nell’ambito del Programma FESR Lazio 2021–2027, Riposizionamento Competitivo RSI, Scienze della Vita, approvato con Determinazione n. G18823 del 28/12/2022, CUP F89J23001060007.
MYTUS è stato coordinato da ADALTIS SRL in collaborazione con CNR IAS I.